Trial record 12 of 75 for:    "frontotemporal dementia with parkinsonism-17" OR "Frontotemporal Dementias" OR "Frontotemporal Dementia"

Far Infrared Irradiation for the Management, Control and Treatment of Frontotemporal Dementia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00674960
First received: May 6, 2008
Last updated: August 14, 2009
Last verified: August 2009
  Purpose

Pick's disease, also known as Pick disease,or FTD is a rare fronto-temporal neurodegenerative disease. This study will investigate the use of far infrared radiation for the control, management and treatment of Pick's disease.


Condition Intervention Phase
Pick Disease of the Brain
Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Management, Control and Treatment of Frontotemporal Dementia (Pick's Disease)

Resource links provided by NLM:


Further study details as provided by GAAD Medical Research Institute Inc.:

Primary Outcome Measures:
  • Therapy for FTD patients [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Rehabilitation of FTD Patients [ Time Frame: 1 Year ] [ Designated as safety issue: No ]

Enrollment: 0
Study Start Date: May 2008
Estimated Study Completion Date: October 2009
Estimated Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Radiation: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation (5μm to 20μm wavelength)

Detailed Description:

This disorder causes progressive destruction of nerve cells in the brain and causes tau proteins to accumulate into the "Pick bodies" that are a defining characteristic of the disease. Tau proteins are microtubule-associated proteins that are abundant in neurons in the central nervous system and are less common elsewhere.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have FTD.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • People with Pick's Disease

Exclusion Criteria:

  • None
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00674960

Locations
Canada, Ontario
The Centre for Incurable Diseases
Toronto, Ontario, Canada, M4V 1L5
Sponsors and Collaborators
GAAD Medical Research Institute Inc.
Investigators
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
  More Information

No publications provided

Responsible Party: : Dr. Kwasi Donyina/Founder and President, GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier: NCT00674960     History of Changes
Other Study ID Numbers: GAAD-FD-CTP1
Study First Received: May 6, 2008
Last Updated: August 14, 2009
Health Authority: Canada: Health Canada

Keywords provided by GAAD Medical Research Institute Inc.:
Brain Atrophy, Circumscribed Lobar
Circumscribed Lobar Atrophy of the Brain
Lobar Atrophy (Brain)
Pick Disease
Pick's Disease
Picks Disease of Brain

Additional relevant MeSH terms:
Frontotemporal Dementia
Pick Disease of the Brain
Aphasia, Primary Progressive
Frontotemporal Lobar Degeneration
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
TDP-43 Proteinopathies
Neurodegenerative Diseases
Proteostasis Deficiencies
Metabolic Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Aphasia
Speech Disorders
Language Disorders
Communication Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Signs and Symptoms

ClinicalTrials.gov processed this record on October 01, 2014